Curasan, a company specializing in bone and tissue regeneration products, has acquired a large part of the oral regenerative medicine division of Riemser Pharma.
Curasan now owns the marketing and distribution rights for the products covered by the contract and is assuming the sales structures, including the national and international customer base, the company noted in a press release.
As a result of this change, Curasan has immediate access to dental markets in the U.S., Canada, Australia, Latin America, Japan, Korea, and China. Other Asian and Eastern European countries will be added upon receipt of the necessary regulatory approvals, which are in process, according to the company.
Riemser acquired Curasan's dental business in 2008.
